

Indikation	Neo-Adjuvant	Adjuvant	Preventiv	Paliativ	Linie	Kurztitel	Vollständiger Titel	ER+ HER2-	ER+ HER+	ER- HER2+	TNBC
AMG-Studien											
Mamma-Ca		x				CAMBRIA-1 EudraCT Number 2022-501024-20-00	A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degradar) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence	x			
Mamma-Ca				x	1	pionERA CO44657 EudraCT Number	A PHASE III RANDOMIZED, OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT , BOTH COMBINED WITH A CDK4/6 INHIBITOR , IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY	x			
Mamma-Ca	x					ADAPT-TN-III EudraCT Number 2023-503605-11-00	NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing sacituzumab govitecan versus sacituzumab govitecan+pembrolizumab in low-risk, triple-negative early breast cancer				x
Mamma-Ca				x	2	ELEMENT GBG-114 EudraCT Number 2023-504925-38-00	Phase II study evaluating the addition of elacestrant , an oral selective estrogen receptor degrader (SERD), to niraparib , a PARP-inhibitor, compared to niraparib alone in patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with g/tBRCA1/2 and/or g/tPALB2 mutations - ELEMENT	x			
Mamma-Ca		x				Caroleen	Eine nicht-interventionelle Studie zu Ribociclib in Kombination mit einem Aromatasehemmer bei Patient*innen mit HR+/HER2- frühem Mammakarzinom im Stadium II und III zur Bewertung der Wirksamkeit, des Sicherheitsprofils, der Therapietreue und der Lebensqualität	x			
Mamma-Ca		x				ASCENT-05 GBG EudraCT Number 2024-512279-10	GS-US-595-6184 Study of Sacituzumab Govitecan -hzyi and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy				x

